title: Role of surgery for optic pathway/hypothalamic astrocytomas in children.
abstract: Optic pathway/hypothalamic pilocytic astrocytomas in children are usually treated with chemotherapy following a surgical biopsy. In this report, we retrospectively considered the role of surgical intervention. In a series of 25 patients without neurofibromatosis type 1, the median age at initial treatment was 3.1 years (range, 0-15 years). Twenty cases were verified by histology, and five cases were diagnosed by MRI findings. Twenty-three patients received chemotherapy. All patients were alive at median follow-up of 66 months. Aims of surgery at the initiation of treatment were biopsy in 12 cases (1 stereotactic and 11 craniotomies) and debulking in 7 cases. The 11 open biopsies revealed pilocytic astrocytoma; however, noticeable complications occurred in five children after the biopsies. Review of preoperative MRIs showed that all had typical findings indicating pilocytic astrocytoma. The open biopsy offered no noteworthy benefit for the patients despite surgical risk and delay of chemotherapy. The extent of the seven resection surgeries was 70% or less removal, and postoperative adjuvant therapy was needed for six of the seven patients. The remaining six children who did not undergo surgery obtained remission with chemotherapy alone. After relapse in nine patients, 15 bulk-reduction surgeries were performed. Surgical resection was not curative in any patient. In five patients, mostly older children, cystic expansion of tumor was partially resected, resulting in additional remission. In conclusion, considering the risk of open surgery and the effectiveness of chemotherapy, the role of surgical intervention is restricted to bulk-reduction surgery only when it is inevitable, especially at relapse after chemotherapy.
authors.affiliation: Department of Neurosurgery, Hokkaido University Hospital, North-15, West-7, Kita-ku, Sapporo 060-8638, Japan. ysawamu@med.hokudai.ac.jp
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Sawamura
authors.forename: Kyousuke
authors.initials: K
authors.lastname: Kamada
authors.forename: Yuuta
authors.initials: Y
authors.lastname: Kamoshima
authors.forename: Shigeru
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Tajima
authors.forename: Junko
authors.initials: J
authors.lastname: Tsubaki
authors.forename: Takamitsu
authors.initials: T
authors.lastname: Fujimaki
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001254:Astrocytoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D006801:Humans; D007029:Hypothalamic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D007223:Infant; D007231:Infant, Newborn; D008279:Magnetic Resonance Imaging; D009364:Neoplasm Recurrence, Local / Q000601:surgery; D019574:Optic Nerve Neoplasms / Q000188:drug therapy / Q000601:surgery*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents